newsfilter
← Latest News
Business Wire·

Cortexyme's Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer's Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

Evidence supports P. gingivalis as a driver of Alzheimer's in easily identified patient population Successful identification of target population and therapeutic dose inform next steps Cortexyme, Inc. (NASDAQ:CRTX) will present additional data fro